Fig. 7
H-LPAEB4−S5−TMPTA administered intratumorally with systemic vorinostat slow the growth of HepG2 subcutaneous xenografts. (a) The xenograft tumor model was established via subcutaneous inoculation of HepG2 cells in BALB/c-nude mice. Mice were randomly divided into three groups and received intratumoral injections of H-LPAEB4−S5−TMPTA synthesized with empty plasmid (Control Empty H-LPAE), intratumoral injections of H-LPAEB4−S5−TMPTA synthesized with empty plasmid and intravenous administration of vorinostat (Empty H-LPAE + vorinostat), and intratumoral injections of H-LPAEB4−S5−TMPTA synthesized with TRAIL plasmid and intravenous administration of vorinostat (TRAIL H-LPAE + vorinostat). The tumors were excised on day 20 and three representative mice in each group were shown. n = 3. (b) The tumor volume progression of nude mice within the observation period. Data is represented as mean ± SD; ns, not significant; *p < 0.05; Student’s t-test. n = 3. (c) Western blot analysis of cleaved Caspase 8, Caspase 8, cleaved Caspase 3, Caspase 3, TRAIL, β-actin in tumor tissues between different groups